Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib

Clinical Chemistry

Volumn 50, Issue 7, 2004, Pages 1233-1237

  Irving, Julie A E ^a,b   O'Brien, Stephen ^a   Lennard, Anne L ^a   Minto, Lynne ^a   Lin, Feng ^a   Hall, Andrew G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; IMATINIB; PHOSPHOTRANSFERASE;

ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC ACCURACY; ELUTION; EXON; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; ONCOGENE; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; EXONS; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MUTATION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 3042614056     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.034801     Document Type: Article

References (23)

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose Ara-C for newly-diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
3. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
4. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
5. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2002;2:99-102.
6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Raquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
7. Shah N, Nicoll J, Nagar B, Gorre M, Raquette R, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
8. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002;99:1860-2.
9. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
10. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359:487-91.
11. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
12. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-8.
13. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293:2163.
14. Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: a review. Hum Mutat 2001;17:439-74.
15. Emmerson P, Maynard J, Jones S, Butler R, Sampson JR, Cheadle JP. Characterizing mutations in samples with low-level mosaicism by collection and analysis of DHPLC fractionated heteroduplexes. Hum Mutat 2003;21:112-5.
16. Antonarakis ES, Sampson JR, Cheadle JP. Temperature modulation of DHPLC analysis for detection of coexisting constitutional and mosaic sequence variants in TSC2. J Biochem Biophys Methods 2002;51:161-4.
17. Roche-Lestienne C, Lai JL, Darre S, Facon T, Preudhomme C. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med 2003;348:2265-6.
18. Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 2003;102:659-61.
19. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
20. Roumianstev S, Shah N, Gorre M, Nicoll J, Brasher BB, Sawyers C. Clinical resistance to the kinase inhibitor STI571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain p-loop. Proc Natl Acad Sci USA 2002;99:10700-5.
21. Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293:2163.
22. Liu WH, Makrigiorgos GM. Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571. Leuk Res 2003;27:979-82.
23. Huang J, Kirk B, Favis R, Soussi T, Paty P, Cao W, et al. An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue. Oncogene 2002;21:1909-21.